Status:
COMPLETED
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression
Lead Sponsor:
University of Turin, Italy
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Based on our previous observations, here the investigator plans to further investigate eNAMPT in MM biology and to establish its role in disease progression where EMT acquisition represents an hallmar...
Detailed Description
Background and preliminary data: Multiple myeloma (MM) is characterized by a clonal expansion of malignant plasma cells in the bone marrow (BM) with a continuous spread of tumour cells in and out of ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Male and female patients over 18 years of age;
- PB-derived serum samples collected in different disease phases (MGUS, SMM, NDMM and RRMM MM patients)
- Sufficient CD138+ cells or RNA from CD138+ cells are available;
- ≥ 2 years median survival data and treatment data is available (progression free and overall survival);
- Bone marrow sample acquired prior to the initiation of the therapy of interest;
- Patients have consented for use of their sample for research purposes.
Exclusion
Key Trial Info
Start Date :
August 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 10 2024
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04137523
Start Date
August 12 2019
End Date
December 10 2024
Last Update
December 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Aou Citta' Della Salute E Della Scienza Di Torino
Torino, TO, Italy, 10126